2-(2,4-dimethoxybenzyl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one | 612530-88-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2,4-dimethoxybenzyl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one
• 英文别名: 2,4-Dimethoxybenzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one；2-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
• CAS: 612530-88-8
• 化学式: C₁₁H₁₄N₂O₅S
• 分子量: 286.309
• InChiKey: PREIJTOUSVTAHE-UHFFFAOYSA-N

物化性质

• 沸点：
  447.1±55.0 °C(Predicted)
• 密度：
  1.395±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  93.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(2,4-dimethoxybenzyl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one 、 4-溴甲基苯甲醛 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 生成 4-[5-(2,4-dimethoxy-benzyl)-1,1,4-trioxo-1,2,5-thiadiazolidin-2-ylmethyl]-benzaldehyde
  参考文献：
  名称：

  [EN] 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS
  [FR] DERIVES 5-SUBSTITUES 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE UTILISES EN TANT QU'INHIBITEURS DE PTPASE 1B

  摘要：

  公式（I）的化合物提供了一种药理剂，它们是PTP酶的抑制剂，特别是公式（I）的化合物抑制PTP-1 B和TC PTP，因此可以用于治疗与PTP酶活性相关的疾病。本发明的化合物还可用于抑制具有磷酸酪氨酸结合区域的其他酶，如SH2结构域。因此，公式（I）的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病相关的胰岛素抵抗。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酸甘油脂血症、动脉粥样硬化、血管再狭窄、肠易激综合症、胰腺炎、脂肪细胞瘤和脂肪肉瘤等癌症、血脂异常以及其他表现出胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性疾病、传染病以及涉及炎症和免疫系统的疾病。

  公开号：

  WO2003082841A1
• 作为产物：
  描述：

  glycine-N-sulfonic acid 2,4-dimethoxybenzylamide 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.17h， 生成 2-(2,4-dimethoxybenzyl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one
  参考文献：
  名称：

  [EN] 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS
  [FR] DERIVES 5-SUBSTITUES 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE UTILISES EN TANT QU'INHIBITEURS DE PTPASE 1B

  摘要：

  公式（I）的化合物提供了一种药理剂，它们是PTP酶的抑制剂，特别是公式（I）的化合物抑制PTP-1 B和TC PTP，因此可以用于治疗与PTP酶活性相关的疾病。本发明的化合物还可用于抑制具有磷酸酪氨酸结合区域的其他酶，如SH2结构域。因此，公式（I）的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病相关的胰岛素抵抗。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酸甘油脂血症、动脉粥样硬化、血管再狭窄、肠易激综合症、胰腺炎、脂肪细胞瘤和脂肪肉瘤等癌症、血脂异常以及其他表现出胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性疾病、传染病以及涉及炎症和免疫系统的疾病。

  公开号：

  WO2003082841A1

文献信息

• 5-Substituted 1,1-dioxo-'1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
  申请人：Coppola Mark Gary

  公开号：US20050090502A1

  公开（公告）日：2005-04-28

  Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式I的化合物提供了药理剂，这些药理剂是PTP酶的抑制剂，特别是公式I的化合物可以抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物还可用于抑制具有磷酸酪氨酸结合区域的其他酶，例如SH2结构域。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病相关的胰岛素抵抗症状。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的多种疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢紊乱以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• Cyclic sulfamide derivatives and methods of use
  申请人：——

  公开号：US20040023974A1

  公开（公告）日：2004-02-05

  Compounds of the formula 1 provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式1的化合物可提供药理学制剂，这些制剂是PTP酶的抑制剂，特别是公式I的化合物抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物也可用于抑制其他具有磷酸酪氨酸结合区域（如SH2结构域）的酶。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• Organic Compounds
  申请人：Barnes David

  公开号：US20080262050A1

  公开（公告）日：2008-10-23

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  式(I)的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，例如SH2结构域。式(I)的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐症、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗。这些疾病包括2型糖尿病的伴随症状，如高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及脂质代谢紊乱和其他胰岛素抵抗相关的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives
  申请人：Novartis AG

  公开号：US07291635B2

  公开（公告）日：2007-11-06

  Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式I的化合物提供了一种PTP酶抑制剂的药理药物，特别是公式I的化合物抑制PTP-1B和TC PTP，因此可以用于治疗与PTP酶活性相关的疾病。本发明的化合物也可以用于抑制其他具有磷酸酪氨酸结合区域的酶，如SH2结构域。因此，公式I的化合物可以用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗症状。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的多种疾病，包括高血脂症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢紊乱以及其他胰岛素抵抗症状的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives
  申请人：Coppola Gary Mark

  公开号：US20080139576A1

  公开（公告）日：2008-06-12

  Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  化合物的公式提供了药理剂，这些药理剂是PTP酶的抑制剂，特别是公式I的化合物抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物也可用于抑制其他具有磷酸酪氨酸结合区域（如SH2结构域）的酶。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗症状。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症、失调脂质代谢和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。